Cargando…
Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation
Hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with malignant hematologic diseases. Killer immunoglobin-like receptor (KIR) expressed by NK cells is closely associated with the transplant outcomes, and it has been widely explored and debated for a few decades. Rece...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901980/ https://www.ncbi.nlm.nih.gov/pubmed/33633734 http://dx.doi.org/10.3389/fimmu.2020.614488 |
_version_ | 1783654467065872384 |
---|---|
author | Zhao, Yanmin Gao, Fei Wu, Yibo Shi, Jimin Luo, Yi Tan, Yamin Yu, Jian Lai, Xiaoyu Zhang, Mingming Zhang, Wei Huang, He |
author_facet | Zhao, Yanmin Gao, Fei Wu, Yibo Shi, Jimin Luo, Yi Tan, Yamin Yu, Jian Lai, Xiaoyu Zhang, Mingming Zhang, Wei Huang, He |
author_sort | Zhao, Yanmin |
collection | PubMed |
description | Hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with malignant hematologic diseases. Killer immunoglobin-like receptor (KIR) expressed by NK cells is closely associated with the transplant outcomes, and it has been widely explored and debated for a few decades. Recently published studies have revealed that inhibitory KIRs (iKIRs) are educated by their cognate human lymphocyte antigen (HLA) ligands, and that decreased iKIR-HLA pairs post-transplantation may indicate a reduced NK cell function and impaired control of the primary disease. However, this theory still needs to be validated by additional clinical studies. Here we conducted a retrospective analysis of 246 patients who received haploidentical (haplo)-HSCT at our treatment center between January 2015 and June 2018. Our data suggests that decreased iKIR-HLA C pair post-HSCT correlated with a significantly higher risk of relapse [hazard risk (HR) = 2.95, p = 0.019] and reduced overall survival (OS) (HR = 3.74, p = 0.001) and disease-free survival (DFS) (HR = 4.05, p = 0.0004) in patients with myeloid disease. In conclusion, decreased iKIR-HLA C pair should be avoided during anti-thymocyte globulin (ATG)-based haplo-HSCT, especially for patients with myeloid disease. |
format | Online Article Text |
id | pubmed-7901980 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79019802021-02-24 Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation Zhao, Yanmin Gao, Fei Wu, Yibo Shi, Jimin Luo, Yi Tan, Yamin Yu, Jian Lai, Xiaoyu Zhang, Mingming Zhang, Wei Huang, He Front Immunol Immunology Hematopoietic stem cell transplantation (HSCT) is a curative therapy for patients with malignant hematologic diseases. Killer immunoglobin-like receptor (KIR) expressed by NK cells is closely associated with the transplant outcomes, and it has been widely explored and debated for a few decades. Recently published studies have revealed that inhibitory KIRs (iKIRs) are educated by their cognate human lymphocyte antigen (HLA) ligands, and that decreased iKIR-HLA pairs post-transplantation may indicate a reduced NK cell function and impaired control of the primary disease. However, this theory still needs to be validated by additional clinical studies. Here we conducted a retrospective analysis of 246 patients who received haploidentical (haplo)-HSCT at our treatment center between January 2015 and June 2018. Our data suggests that decreased iKIR-HLA C pair post-HSCT correlated with a significantly higher risk of relapse [hazard risk (HR) = 2.95, p = 0.019] and reduced overall survival (OS) (HR = 3.74, p = 0.001) and disease-free survival (DFS) (HR = 4.05, p = 0.0004) in patients with myeloid disease. In conclusion, decreased iKIR-HLA C pair should be avoided during anti-thymocyte globulin (ATG)-based haplo-HSCT, especially for patients with myeloid disease. Frontiers Media S.A. 2021-02-04 /pmc/articles/PMC7901980/ /pubmed/33633734 http://dx.doi.org/10.3389/fimmu.2020.614488 Text en Copyright © 2021 Zhao, Gao, Wu, Shi, Luo, Tan, Yu, Lai, Zhang, Zhang and Huang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Zhao, Yanmin Gao, Fei Wu, Yibo Shi, Jimin Luo, Yi Tan, Yamin Yu, Jian Lai, Xiaoyu Zhang, Mingming Zhang, Wei Huang, He Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation |
title | Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation |
title_full | Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation |
title_fullStr | Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation |
title_full_unstemmed | Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation |
title_short | Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation |
title_sort | decreased ikir-hla c pair confers worse clinical outcomes for patients with myeloid disease receiving antithymocyte globulin-based haploidentical hematopoietic stem cell transplantation |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901980/ https://www.ncbi.nlm.nih.gov/pubmed/33633734 http://dx.doi.org/10.3389/fimmu.2020.614488 |
work_keys_str_mv | AT zhaoyanmin decreasedikirhlacpairconfersworseclinicaloutcomesforpatientswithmyeloiddiseasereceivingantithymocyteglobulinbasedhaploidenticalhematopoieticstemcelltransplantation AT gaofei decreasedikirhlacpairconfersworseclinicaloutcomesforpatientswithmyeloiddiseasereceivingantithymocyteglobulinbasedhaploidenticalhematopoieticstemcelltransplantation AT wuyibo decreasedikirhlacpairconfersworseclinicaloutcomesforpatientswithmyeloiddiseasereceivingantithymocyteglobulinbasedhaploidenticalhematopoieticstemcelltransplantation AT shijimin decreasedikirhlacpairconfersworseclinicaloutcomesforpatientswithmyeloiddiseasereceivingantithymocyteglobulinbasedhaploidenticalhematopoieticstemcelltransplantation AT luoyi decreasedikirhlacpairconfersworseclinicaloutcomesforpatientswithmyeloiddiseasereceivingantithymocyteglobulinbasedhaploidenticalhematopoieticstemcelltransplantation AT tanyamin decreasedikirhlacpairconfersworseclinicaloutcomesforpatientswithmyeloiddiseasereceivingantithymocyteglobulinbasedhaploidenticalhematopoieticstemcelltransplantation AT yujian decreasedikirhlacpairconfersworseclinicaloutcomesforpatientswithmyeloiddiseasereceivingantithymocyteglobulinbasedhaploidenticalhematopoieticstemcelltransplantation AT laixiaoyu decreasedikirhlacpairconfersworseclinicaloutcomesforpatientswithmyeloiddiseasereceivingantithymocyteglobulinbasedhaploidenticalhematopoieticstemcelltransplantation AT zhangmingming decreasedikirhlacpairconfersworseclinicaloutcomesforpatientswithmyeloiddiseasereceivingantithymocyteglobulinbasedhaploidenticalhematopoieticstemcelltransplantation AT zhangwei decreasedikirhlacpairconfersworseclinicaloutcomesforpatientswithmyeloiddiseasereceivingantithymocyteglobulinbasedhaploidenticalhematopoieticstemcelltransplantation AT huanghe decreasedikirhlacpairconfersworseclinicaloutcomesforpatientswithmyeloiddiseasereceivingantithymocyteglobulinbasedhaploidenticalhematopoieticstemcelltransplantation |